NEW YORK (GenomeWeb) – Atlanta-based Cocrystal Pharma today announced licensing agreements with Duke University and Emory University for CRISPR/Cas9 technologies to be used in developing and commercializing antiviral therapeutics for hepatitis B virus (HBV) and human papilloma virus (HPV).

"We are excited to explore the CRISPR/Cas technologies to potentially develop the first virus-targeted genome-modifying treatment that may be able to provide a cure for HPV and HBV," Cocrystal CEO Jeffrey Meckler said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.